Postoperative Radiotherapy for Early-stage Oral Tongue Squamous Cell Carcinoma Patients With Risk Factors: a Prospective, Multicenter, Randomized Controlled, Open-labelled Trial
Second Affiliated Hospital, School of Medicine, Zhejiang University
190 participants
Jan 26, 2026
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to learn whether postoperative radiotherapy can delay disease recurrence in patients with early-stage oral squamous cell carcinoma who have high-risk factors. The main question it aims to answer is: Is the clinical outcome of early-stage tongue squamous cell carcinoma patients with risk factors after tumor enlargement resection receiving postoperative radiotherapy better than that of patients with simple follow-up observation? How is the safety? Researchers will compare the postoperative radiotherapy group and the simple follow-up observation group to see if there are differences between the two groups in terms of 3-year disease-free survival rate, 5-year disease-free survival rate, overall survival rate, toxicity events, and quality of life. Participants of postoperative radiotherapy group will receive postoperative radiotherapy 6-8 weeks after surgery.
Eligibility
Inclusion Criteria9
- Age ≥ 18 years old and ≤ 70 years old, gender not limited;
- Newly treated patients (who have not undergone radiotherapy, chemotherapy, or targeted therapy before);
- Complete resection of the tumor with naked eye and no residual tumor observed in postoperative pathology;
- The lesion is limited to the anterior 2/3 of the tongue (active part of the tongue);
- Postoperative pathological diagnosis was squamous cell carcinoma of the tongue;
- According to AJCC 8th edition, the pathological TNM staging is T1-2N0M0;
- Having at least one risk factor: vascular cancer thrombus, nerve invasion, moderate or low differentiation;
- The general status score of the Eastern Cancer Collaboration Group (ECOG) is 0-2 points;
- Not participating in other clinical trials within the previous 4 weeks prior to screening; If other trials fail to screen cases, but meet the requirements of this trial, they can be enrolled.
Exclusion Criteria9
- Patients who invade the oropharynx, mouth floor, cheeks, neck, and other organs;
- Have received chemotherapy or other anti-tumor drugs;
- Previously received radiation therapy for the head and neck area;
- Patients with active autoimmune diseases that require systemic treatment in the past;
- Pregnant or lactating women;
- Individuals with acute infections that are difficult to control;
- Patients with drug abuse, drug abuse, long-term alcoholism and AIDS;
- The subjects also have other known invasive malignant tumors (excluding those with no evidence of tumor recurrence through treatment and a duration of more than 2 years);
- Researchers believe that there are other conditions that hinder patients from participating in this trial.
Interventions
Radiation therapy should commence immediately after the surgical wound has fully healed, typically 4 to 6 weeks post-operation, but no later than 8 weeks post-operation
Locations(28)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07402525